Showing results (161-170 of 202) with videos related to

Sort By:
Pageof 21
The Journal of Infectious Diseases|August 27, 2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359Roy M Gulick, X Joan Hu, Susan A Fiscus, et al.
AIDS (London, England)|April 7, 2007
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppressionRoy M Gulick, Christina M Lalama, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 21, 2014
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimensYu Zheng, Michael D Hughes, Shahin Lockman, et al.
The Journal of Infectious Diseases|October 17, 2006
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086Constance A Benson, Florin Vaida, Diane V Havlir, et al.
AIDS (London, England)|November 7, 2015
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recoveryAnthony R Cillo, Benedict B Hilldorfer, Christina M Lalama, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 7, 2005
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)Andrew R Zolopa, Laura C Lazzeroni, Alex Rinehart, et al.
Lancet (London, England)|April 14, 2009
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies, Jonathan A C Sterne, Margaret May, et al.
The Journal of Infectious Diseases|July 29, 2010
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group studyHeather J Ribaudo, Huan Liu, Matthias Schwab, et al.
The Journal of Infectious Diseases|March 5, 2004
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIVJoseph J Eron, Roy M Gulick, John A Bartlett, et al.
Pageof 21